

AMENDMENTS TO THE SPECIFICATION

Please delete the first full paragraph on page 3 in the specification, and replace with the following new one:

In addition to these, ~~JP-A-6-87742~~EP0531219A1 describes that histamine H₃ receptor ~~antagonists-agonists~~ can be expected to be applicable as an anti-migraine tranquilizer, sleep-inducer, an hypnotic, sedative, anxiolytic, anti-asthmatic and anti-inflammatory agent, notably for the bronchi, the skin or eyes, or as an anti-gastric ulcer agent, and the like. In addition, International Publication WO 2001/6865, International Publication WO 99/05115, International Publication WO 99/05141, International Publication WO 99/05141 and the like describe that it is possible to use histamine H₃ receptor ligands as therapeutic agents for obesity, type II diabetes, epilepsy, sleep disorders, depression, Alzheimer disease and the like.

Please replace the second full paragraph bridging pages 3-4 in the specification, and replace with the following new one:

As an example of a histamine H₃ receptor ligand screened from natural resources, verongamine isolated from a sponge has been reported [Mierzwa *et al.*, *J. Nat. Prod.*, vol. 57, pp. 175 – 177, 1994]. Including Verongamine, most of the conventional histamine H₃ receptor ligands have imidazole ~~structurering~~, which is present in the structure of the endogenous ligand histamine. However, the PF1270A, B and C substances of the present application are novel histamine H₃ receptor ligands which do not have the imidazole ~~structurering~~. Known microbial products structurally related to the compounds of the present invention include Marcfortine A which was reported for the treatment and prevention of parasitic diseases [Polonsky *et al.*, *J. Chem. Soc. Chem. Commun.*, pp. 601 – 602, 1980, US Patent 4,866,060], and the like. However, the compounds of the present application are novel substances whose structures are different from those of the already known compounds so far reported.